Cargando…
Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022
IMPORTANCE: Estimating the true burden of SARS-CoV-2 infection has been difficult in sub-Saharan Africa owing to asymptomatic infections and inadequate testing capacity. Antibody responses from serologic surveys can provide an estimate of SARS-CoV-2 exposure at the population level. OBJECTIVE: To es...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932849/ https://www.ncbi.nlm.nih.gov/pubmed/36790811 http://dx.doi.org/10.1001/jamanetworkopen.2022.55978 |
_version_ | 1784889548487000064 |
---|---|
author | Briggs, Jessica Takahashi, Saki Nayebare, Patience Cuu, Gloria Rek, John Zedi, Maato Kizza, Timothy Arinaitwe, Emmanuel Nankabirwa, Joaniter I. Kamya, Moses Jagannathan, Prasanna Jacobson, Karen Rosenthal, Philip J. Dorsey, Grant Greenhouse, Bryan Ssewanyana, Isaac Rodríguez-Barraquer, Isabel |
author_facet | Briggs, Jessica Takahashi, Saki Nayebare, Patience Cuu, Gloria Rek, John Zedi, Maato Kizza, Timothy Arinaitwe, Emmanuel Nankabirwa, Joaniter I. Kamya, Moses Jagannathan, Prasanna Jacobson, Karen Rosenthal, Philip J. Dorsey, Grant Greenhouse, Bryan Ssewanyana, Isaac Rodríguez-Barraquer, Isabel |
author_sort | Briggs, Jessica |
collection | PubMed |
description | IMPORTANCE: Estimating the true burden of SARS-CoV-2 infection has been difficult in sub-Saharan Africa owing to asymptomatic infections and inadequate testing capacity. Antibody responses from serologic surveys can provide an estimate of SARS-CoV-2 exposure at the population level. OBJECTIVE: To estimate SARS-CoV-2 seroprevalence, attack rates, and reinfection in eastern Uganda using serologic surveillance from 2020 to early 2022. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted in the Tororo and Busia districts of eastern Uganda. Plasma samples from participants in the Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in Uganda Border Cohort were obtained at 4 sampling intervals: October to November 2020, March to April 2021, August to September 2021, and February to March 2022. Each participant contributed up to 4 time points for SARS-CoV-2 serology, with almost half of all participants contributing at all 4 time points, and almost 90% contributing at 3 or 4 time points. Information on SARS-CoV-2 vaccination status was collected from participants, with the earliest reported vaccinations in the cohort occurring in May 2021. MAIN OUTCOMES AND MEASURES: The main outcomes of this study were antibody responses to the SARS-CoV-2 spike protein as measured with a bead-based serologic assay. Individual-level outcomes were aggregated to population-level SARS-CoV-2 seroprevalence, attack rates, and boosting rates. Estimates were weighted by the local age distribution according to census data. RESULTS: A total of 1483 samples from 441 participants living in 76 households were tested. Of the 441 participants, 245 (55.6%) were female, and their mean (SD) age was 16.04 (16.04) years. By the end of the Delta wave and before widespread vaccination, adjusted SARS-CoV-2 seroprevalence was 67.7% (95% credible interval [CrI], 62.5%-72.6%) in the study population. During the subsequent Omicron wave, 84.8% (95% CrI, 67.9%-93.7%) of unvaccinated, previously seronegative individuals were infected for the first time, and 50.8% (95% CrI, 40.6%-59.7%) of unvaccinated, already seropositive individuals were likely reinfected, leading to an overall seropositivity of 96.0% (95% CrI, 93.4%-97.9%) in this population. These results suggest a lower probability of reinfection in individuals with higher preexisting antibody levels. There was evidence of household clustering of SARS-CoV-2 seroconversion. No significant associations were found between SARS-CoV-2 seroconversion and gender, household size, or recent Plasmodium falciparum malaria exposure. CONCLUSIONS AND RELEVANCE: In this cohort study in a rural population in eastern Uganda, there was evidence of very high SARS-CoV-2 infection rates throughout the pandemic inconsistent with national level case data and high reinfection rates during the Omicron wave. |
format | Online Article Text |
id | pubmed-9932849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-99328492023-02-17 Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022 Briggs, Jessica Takahashi, Saki Nayebare, Patience Cuu, Gloria Rek, John Zedi, Maato Kizza, Timothy Arinaitwe, Emmanuel Nankabirwa, Joaniter I. Kamya, Moses Jagannathan, Prasanna Jacobson, Karen Rosenthal, Philip J. Dorsey, Grant Greenhouse, Bryan Ssewanyana, Isaac Rodríguez-Barraquer, Isabel JAMA Netw Open Original Investigation IMPORTANCE: Estimating the true burden of SARS-CoV-2 infection has been difficult in sub-Saharan Africa owing to asymptomatic infections and inadequate testing capacity. Antibody responses from serologic surveys can provide an estimate of SARS-CoV-2 exposure at the population level. OBJECTIVE: To estimate SARS-CoV-2 seroprevalence, attack rates, and reinfection in eastern Uganda using serologic surveillance from 2020 to early 2022. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted in the Tororo and Busia districts of eastern Uganda. Plasma samples from participants in the Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in Uganda Border Cohort were obtained at 4 sampling intervals: October to November 2020, March to April 2021, August to September 2021, and February to March 2022. Each participant contributed up to 4 time points for SARS-CoV-2 serology, with almost half of all participants contributing at all 4 time points, and almost 90% contributing at 3 or 4 time points. Information on SARS-CoV-2 vaccination status was collected from participants, with the earliest reported vaccinations in the cohort occurring in May 2021. MAIN OUTCOMES AND MEASURES: The main outcomes of this study were antibody responses to the SARS-CoV-2 spike protein as measured with a bead-based serologic assay. Individual-level outcomes were aggregated to population-level SARS-CoV-2 seroprevalence, attack rates, and boosting rates. Estimates were weighted by the local age distribution according to census data. RESULTS: A total of 1483 samples from 441 participants living in 76 households were tested. Of the 441 participants, 245 (55.6%) were female, and their mean (SD) age was 16.04 (16.04) years. By the end of the Delta wave and before widespread vaccination, adjusted SARS-CoV-2 seroprevalence was 67.7% (95% credible interval [CrI], 62.5%-72.6%) in the study population. During the subsequent Omicron wave, 84.8% (95% CrI, 67.9%-93.7%) of unvaccinated, previously seronegative individuals were infected for the first time, and 50.8% (95% CrI, 40.6%-59.7%) of unvaccinated, already seropositive individuals were likely reinfected, leading to an overall seropositivity of 96.0% (95% CrI, 93.4%-97.9%) in this population. These results suggest a lower probability of reinfection in individuals with higher preexisting antibody levels. There was evidence of household clustering of SARS-CoV-2 seroconversion. No significant associations were found between SARS-CoV-2 seroconversion and gender, household size, or recent Plasmodium falciparum malaria exposure. CONCLUSIONS AND RELEVANCE: In this cohort study in a rural population in eastern Uganda, there was evidence of very high SARS-CoV-2 infection rates throughout the pandemic inconsistent with national level case data and high reinfection rates during the Omicron wave. American Medical Association 2023-02-15 /pmc/articles/PMC9932849/ /pubmed/36790811 http://dx.doi.org/10.1001/jamanetworkopen.2022.55978 Text en Copyright 2023 Briggs J et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License. |
spellingShingle | Original Investigation Briggs, Jessica Takahashi, Saki Nayebare, Patience Cuu, Gloria Rek, John Zedi, Maato Kizza, Timothy Arinaitwe, Emmanuel Nankabirwa, Joaniter I. Kamya, Moses Jagannathan, Prasanna Jacobson, Karen Rosenthal, Philip J. Dorsey, Grant Greenhouse, Bryan Ssewanyana, Isaac Rodríguez-Barraquer, Isabel Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022 |
title | Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022 |
title_full | Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022 |
title_fullStr | Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022 |
title_full_unstemmed | Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022 |
title_short | Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022 |
title_sort | seroprevalence of antibodies to sars-cov-2 in rural households in eastern uganda, 2020-2022 |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932849/ https://www.ncbi.nlm.nih.gov/pubmed/36790811 http://dx.doi.org/10.1001/jamanetworkopen.2022.55978 |
work_keys_str_mv | AT briggsjessica seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT takahashisaki seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT nayebarepatience seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT cuugloria seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT rekjohn seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT zedimaato seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT kizzatimothy seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT arinaitweemmanuel seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT nankabirwajoaniteri seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT kamyamoses seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT jagannathanprasanna seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT jacobsonkaren seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT rosenthalphilipj seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT dorseygrant seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT greenhousebryan seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT ssewanyanaisaac seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 AT rodriguezbarraquerisabel seroprevalenceofantibodiestosarscov2inruralhouseholdsineasternuganda20202022 |